Cornea

Espansione Group's Light Modulation Low-level Light Therapy (LLLT) is used in ophthalmology and dermatology

Research data published earlier this year could help clinicians gain a better understanding of what to look for in a specular microscope, and how to interpret inter- and intradevice repeatability results in a way that benefits their existing practice framework.

VisiRose, a company formed in collaboration with Provectus Biopharmaceuticals and the University of Miami Miller School of Medicine’s Bascom Palmer Eye Institute, is advancing Rose Bengal Photodynamic Antimicrobial Therapy (RB PDAT), a non-invasive treatment for infectious keratitis, leveraging light-based technology and addressing antimicrobial resistance to improve outcomes for patients with severe eye infections globally.

BostonSight’s pilot study, published in Clinical Ophthalmology, explores the use of PROSE scleral lenses as a drug delivery system for cyclosporine 0.05% in treating dry eye disease, showing promising symptom relief and tolerability.

The authors analysed severity and frequency of ocular pain among patients with DED living in altitudes above 2,500 meters during the COVID-19 pandemic

The incidence was comparable to that of daily wear soft contact lenses.

The incidence was comparable to that of daily wear soft contact lenses

A Q&A with PPP Committee Cornea/External Disease Panel member Daniel S. Choi, MD.

A discussion with Shigeru Kinoshita, MD, PhD; and Edward J. Holland, MD.

The EnVision Summit, co-founded by Bonnie An Henderson, MD, is a unique family-oriented, multispecialty ophthalmology CME conference, along with a newly introduced optometry track. Henderson sits down with Ophthalmology Times to talk about the 2025 conference that will take place February 14 to 17 at the Caribe Hilton San Juan, in Puerto Rico.

Emmecell announced positive Phase 1 extension study results for EO2002, a nonsurgical cell therapy for corneal edema. The therapy improved vision, reduced central corneal thickness, and demonstrated strong safety, offering an alternative to corneal transplants.

Assessing two devices in a real-world setting

Investigators from Bergen, Norway, and Cleveland, Ohio, collaborated on the predictive model

Research indicates suppressive valacyclovir could help patients avoid keratitis and iritis flare-ups

Corneal confocal microscopy, semaglutide therapy offer treatment options

The authors reported significant variability in DED-related symptoms, with higher prevalence rates among university students and administrative workers

A study led by researchers at the University of Birmingham finds AI-powered models can match ophthalmologists in diagnosing infectious keratitis, offering promise for global eye care improvements.

John D. Sheppard, MD, MMSc, FACS, spoke with the Eye Care Network to provide some insight on post hoc analysis of the ESSENCE 1 trial dor dry eye disease.

According to OKYO Pharma, OK-101 is the first drug candidate to enroll patients specifically diagnosed with neuropathic corneal pain in a clinical trial. The Phase 2 trial is designed as a randomized, placebo-controlled, double-masked study to treat 48 NCP patients.

Farhad Hafezi, FARVO, MD, PhD, and colleagues reported on results achieved with phototherapeutic keratectomy-assisted, customised, epi-on corneal crosslinking

Dry eye increases susceptibility to psychiatric disorders and chronic pain syndromes, investigators reported at the 2024 AAO meeting

According to the company, in a confirmatory trial, Epioxa met pre-specified primary efficacy endpoint and exhibited positive tolerability and safety profiles through 12 months, supporting an anticipated NDA submission by the end of 2024.

A Norwegian study demonstrates that transplant rates continue to drop over time

The trial is assessing the safety and efficacy of EO2002 for the treatment of corneal edema.

Ciclosporin 0.1% eye drops solution will be marketed under the brand name Vevizye in the EU for the treatment of dry eye disease